Halozyme Therapeutics
HALO
$51.77
Share price
1.27%
Change (1 day)
49.58%
Change (1 year)
Categories
P/S ratio for Halozyme Therapeutics (HALO)
P/S ratio as of January 2023 (TTM): 12.0
According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.0176. At the end of 2022 the company had a P/S ratio of 9.49.
P/S ratio history for Halozyme Therapeutics from 2005 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 9.49 | -25.72% |
| 2021 | 12.8 | -40.81% |
| 2020 | 21.6 | 74.46% |
| 2019 | 12.4 | -11.3% |
| 2018 | 13.9 | 53.06% |
| 2017 | 9.11 | 4.45% |
| 2016 | 8.72 | -46.96% |
| 2015 | 16.4 | 2.11% |
| 2014 | 16.1 | -48.6% |
| 2013 | 31.3 | 75.34% |
| 2012 | 17.9 | 1.63% |
| 2011 | 17.6 | -69.93% |
| 2010 | 58.5 | 48.53% |
| 2009 | 39.4 | -24.36% |
| 2008 | 52.0 | -64.3% |
| 2007 | 146 | -74.13% |
| 2006 | 564 | -33.42% |
| 2005 | 847 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.40 | -63.38% | 🇺🇸 USA |
 Pfizer PFE | 2.44 | -79.66% | 🇺🇸 USA |
 Eli Lilly LLY | 11.1 | -7.97% | 🇺🇸 USA |
 Sanofi SNY | 2.60 | -78.38% | 🇫🇷 France |
 Baxter BAX | 1.56 | -87.02% | 🇺🇸 USA |
 MannKind Corp MNKD | 18.6 | 55.15% | 🇺🇸 USA |